Halozyme Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $2,453 Mil.
Halozyme Therapeutics's quarterly Total Liabilities
increased
from Sep. 2025 ($1,717.32 Mil) to Dec. 2025 ($2,476.51 Mil) but then
declined
from Dec. 2025 ($2,476.51 Mil) to Mar. 2026 ($2,453.08 Mil).
Halozyme Therapeutics's annual Total Liabilities
increased
from Dec. 2023 ($1,649.46 Mil) to Dec. 2024 ($1,699.66 Mil) and
increased
from Dec. 2024 ($1,699.66 Mil) to Dec. 2025 ($2,476.51 Mil).
Halozyme Therapeutics Total Liabilities Related Terms
Halozyme Therapeutics Total Liabilities Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Halozyme Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (HALO) has a Total Liabilities of $2,453 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Total Liabilities too high?
Halozyme Therapeutics' current Total Liabilities is $2,453 Mil. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Total Liabilities compare to KYMR and IBRX?
Halozyme Therapeutics' Total Liabilities of $2,453 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Total Liabilities is $2,453 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.71, compared to a current price of $79.47 — trading 12.4% below its estimated fair value. The current Total Liabilities is $2,453 Mil. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Total Liabilities is $2,453 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $79.47 is trading 12.4% below its estimated GF Value™ of $90.71.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
Total Liabilities: $2,453 Mil
GF Value™: $90.71 vs. price of $79.47 (12.4% below fair value)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score
Get the complete analysis for HALO
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
